Rhenman & Partners Asset Management Ab Pliant Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 120,250 shares of PLRX stock, worth $1.48 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
120,250
Previous 120,250
-0.0%
Holding current value
$1.48 Million
Previous $1.29 Million
4.33%
% of portfolio
0.11%
Previous 0.13%
Shares
4 transactions
Others Institutions Holding PLRX
# of Institutions
168Shares Held
63.2MCall Options Held
245KPut Options Held
373K-
Deep Track Capital, LP Greenwich, CT5.97MShares$73.6 Million2.47% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$61.3 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.83MShares$59.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.53MShares$43.4 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.2MShares$39.4 Million2.34% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $600M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...